Display options
Cite
van Nooten F, Davies GM, Jukema JW, et al. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Neth Heart J. 2011;19(2):61-7doi: 10.1007/s12471-010-0061-5.
van Nooten, F., Davies, G. M., Jukema, J. W., Liem, A. H., Yap, E., & Hu, X. H. (2011). Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 19(2), 61-7. https://doi.org/10.1007/s12471-010-0061-5
van Nooten, F, et al. "Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia." Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation vol. 19,2 (2011): 61-7. doi: https://doi.org/10.1007/s12471-010-0061-5
van Nooten F, Davies GM, Jukema JW, Liem AH, Yap E, Hu XH. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Neth Heart J. 2011 Feb;19(2):61-7. doi: 10.1007/s12471-010-0061-5. PMID: 22020943; PMCID: PMC3077851.
Copy Download .nbib Format: NLM
Share it on

Neth Heart J. 2011 Feb;19(2):61-7. doi: 10.1007/s12471-010-0061-5.

Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

F van Nooten, G M Davies, J W Jukema, A H Liem, E Yap, X H Hu

Affiliations

  1. United BioSource Corporation, 26-28 Hammersmith Grove, London, W6 7HA, UK, [email protected].

PMID: 22020943 PMCID: PMC3077851 DOI: 10.1007/s12471-010-0061-5

Abstract

OBJECTIVE: This study aims to assess the cost-effectiveness of ezetimibe plus simvastatin (E/S) versus atorvastatin or simvastatin monotherapy as second-line treatment of primary hypercholesterolaemia from the Dutch healthcare perspective.

METHODS: The evaluation used a Markov model and patient data from the Dutch EASEGO study in which patients failing to reach goal low-density lipoprotein cholesterol levels on atorvastatin 10 mg or simvastatin 20 mg had their dose doubled or switched to ezetimibe 10 mg plus generic simvastatin 20 mg (E10/S20). The second scenario, based on Dutch guidelines, switched patients from simvastatin 40 mg to atorvastatin 40 mg, or ezetimibe 10 mg was added to simvastatin 40 mg (E10/S40). The key effectiveness input measure was change in total cholesterol/high-density lipoprotein ratio obtained from the EASEGO study. In conformity with published studies linking reduced lipid levels to reduced risk of cardiovascular events, the present model assumed that a lipid decrease with ezetimibe may be a signal for reduced risk of cardiovascular events. Model parameters were derived from published literature. Sensitivity analyses were performed for the key parameters.

RESULTS: In the EASEGO scenario, incremental cost-effectiveness ratio for E10/S20 was 3497/quality-adjusted life-years (QALY) vs atorvastatin 20 mg and 26,417/QALY vs simvastatin 40 mg. In the Dutch guidelines scenario, E10/S40 was dominant (more effective and cost-saving) vs atorvastatin 40 mg. Varying model inputs had limited impact on the cost-effectiveness of E/S.

CONCLUSIONS: The analysis showed the cost-effectiveness of E/S versus atorvastatin 20 mg or simvastatin 40 mg (EASEGO scenario) at a threshold of 30,000/QALY and vs atorvastatin 40 mg was dominant (Dutch guidelines). Thus, E/S seems a valuable cost-effective second-line treatment option for patients not attaining lipid treatment goals.

References

  1. Pharmacoeconomics. 2006;24(8):815-30 - PubMed
  2. Conn Med. 2005 Jan;69(1):19-22 - PubMed
  3. Am Heart J. 2000 Feb;139(2 Pt 1):272-81 - PubMed
  4. Cardiology. 2009;113(2):89-97 - PubMed
  5. Am Heart J. 2010 May;159(5):705-9 - PubMed
  6. Curr Med Res Opin. 2010 Jan;26(1):25-36 - PubMed
  7. Expert Opin Drug Saf. 2009 Nov;8(6):715-25 - PubMed
  8. Circulation. 2008 Jun 3;117(22):2875-83 - PubMed
  9. Mayo Clin Proc. 2004 May;79(5):620-9 - PubMed
  10. BMJ. 2004 Jan 31;328(7434):254 - PubMed
  11. Eur Heart J. 2001 May;22(9):751-61 - PubMed
  12. Clin Ther. 2008 Aug;30(8):1508-23 - PubMed
  13. Ned Tijdschr Geneeskd. 2005 Jul 9;149(28):1574-8 - PubMed
  14. Eur Heart J. 2008 Apr;29(7):849-58 - PubMed
  15. Pharmacoeconomics. 2004;22 Suppl 3:37-48 - PubMed
  16. BMJ. 2003 Jun 28;326(7404):1423 - PubMed
  17. Int J Clin Pract. 2009 Apr;63(4):547-59 - PubMed
  18. Int J Clin Pract. 2008 Apr;62(4):539-54 - PubMed
  19. Curr Med Res Opin. 2008 Oct;24(10):2953-66 - PubMed
  20. Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):183-8 - PubMed
  21. J Am Coll Cardiol. 2008 Dec 16;52(25):2198-205 - PubMed
  22. JAMA. 2001 Jul 11;286(2):180-7 - PubMed
  23. N Engl J Med. 2008 Sep 25;359(13):1343-56 - PubMed
  24. Ann Acad Med Singap. 2009 Jun;38(6):541-5 - PubMed
  25. Pharmacoeconomics. 2004;22 Suppl 3:49-61 - PubMed
  26. Curr Med Res Opin. 2008 Mar;24(3):685-94 - PubMed

Publication Types